Bayesian Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bayesian Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-54,700	Closed	-$452K	–	707
2021 Q1	$452K	Buy	54,700 +24,100	+79%	+$254K	0.1%	248
2020 Q4	$209K	Buy	+30,600	New	+$246K	0.05%	374

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bayesian Capital Management's SRNE Position: Q2 2021 in Review

Bayesian Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 54,700 shares — an estimated $452K sold.

Bayesian Capital Management first reported a position in SRNE in Q4 2020 and held it in 2 quarters. The position peaked at $452K in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

Bayesian Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Bayesian Capital Management sold 54,700 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $452K.
Bayesian Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
Bayesian Capital Management's Sorrento Therapeutics, Inc. position peaked at $452K in Q1 2021.
212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Bayesian Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.